Drug Pipeline

Insulin Degludec Injection Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
1
Phase 3
4
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-05 NCT07630233 A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… Phase 1 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07527078 Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes Type 2 Diabetes (T2DM) Not Yet Recruiting
Phase 1
NCT06280703 A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes… Healthy Recruiting
NCT07032688 A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of… Type 2 Diabetes Recruiting
NCT07630233 A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… Type 2 Diabetes Mellitus (T2DM) Not Yet Recruiting
Sponsors Running Insulin Degludec Injection Trials
Eli Lilly and Company (1) Jiangsu HengRui Medicine Co., Ltd. (1) Gan & Lee Pharmaceuticals. (1) The United Bio-Technology (Hengqin) Co., Ltd. (1)
Disease Areas
Diabetes (4) Type 2 Diabetes (3) Type 1 Diabetes (1)
Get alerts when Insulin Degludec Injection trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free